PLX

Over the past six months, Protalix Biotherapeutics' stock has been influenced by several financial and regulatory announcements. Q2 2026 financial results reported EPS of $0.05 and revenue of $19.9 million, significantly exceeding analyst expectations. Q1 2026 financial results also showed a positive EPS of $0.22, beating estimates. The European Commission's approval of an additional dosing regimen for Elfabrio in March 2026 was a positive regulatory event. Conversely, Q4 2025 and Q3 2025 financial results reported EPS of -$0.06 and $0.03 respectively, both missing analyst estimates. Consensus EPS estimates for fiscal year 2026 increased by 26%, and the 2026 revenue forecast was raised. As of September 18, 2026, the share price was $2.70, representing a 43.12% increase from the previous year, with a 52-week range between $1.60 and $3.19.